Want to see HK:6609 full AI Analyst Report?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) AI Stock Analysis
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
(HKEX:6609)
Strong financial performance from rapid revenue growth and path to profitability is the primary driver. Bullish technical indicators reinforce positive momentum, while fair valuation supports the score.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 2.19B
- Dividend Yield
- ―
- Average Volume (3M)
- 41.60K
- Price to Earnings (P/E)
- 18.2
- Beta (1Y)
- 0.84
- Revenue Growth
- 59.30%
- EPS Growth
- 131.03%
- Country
- Hong Kong
- Employees
- 425
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai HeartCare Medical Technology Corporation Limited is a global enterprise specializing in the research, development, manufacturing, and commercialization of neuro-interventional medical devices. Its extensive product range encompasses devices...
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview
Summary
Robust revenue growth from $14.6M to projected $397.7M by 2025, gross margins to 69%, shift to 20% net margin and positive cash flow, with low debt supporting stability.
Income Statement
85Very PositiveBalance Sheet
80PositiveCash Flow
75Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 513.79M | 408.29M | 277.90M | 232.34M | 183.03M | 90.09M |
| Gross Profit | 353.55M | 272.17M | 181.72M | 151.79M | 124.33M | 54.95M |
| EBITDA | 113.69M | 72.56M | 21.87M | -68.50M | -167.31M | -183.34M |
| Net Income | 92.76M | 83.33M | -13.62M | -94.01M | -200.38M | -194.22M |
Balance Sheet | ||||||
| Total Assets | 1.37B | 1.29B | 1.21B | 1.20B | 1.31B | 1.50B |
| Cash, Cash Equivalents and Short-Term Investments | 789.70M | 786.81M | 713.72M | 721.14M | 870.12M | 1.22B |
| Total Debt | 41.22M | 42.74M | 35.75M | 36.38M | 50.69M | 41.94M |
| Total Liabilities | 152.73M | 133.50M | 144.00M | 125.60M | 147.08M | 132.10M |
| Stockholders Equity | 1.22B | 1.13B | 1.06B | 1.08B | 1.17B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 97.61M | 139.98M | -8.39M | -137.72M | -304.01M | -260.33M |
| Operating Cash Flow | 105.51M | 154.14M | -3.23M | -88.41M | -266.77M | -205.85M |
| Investing Cash Flow | -90.02M | -253.09M | 10.80M | -125.45M | 44.84M | -161.10M |
| Financing Cash Flow | -31.71M | -44.73M | -12.38M | -21.48M | -24.75M | 821.25M |
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6609, the sentiment is Positive. The current price of 53.20 is below the 20-day moving average (MA) of 54.44, above the 50-day MA of 52.17, and above the 200-day MA of 49.42, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 49.76 is Neutral, neither overbought nor oversold. The STOCH value of 43.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6609.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison
Overall Rating
- HK:660979Outperform
HK:130256Neutral
HK:999648Neutral
HK:250044Neutral
HK:216043Neutral
HK:085341Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6609 | 79Outperform | HKD 2.18B | 18.20 | 7.90% | ― | 59.30% | 131.03% |
| HK:1302 | 56Neutral | HKD 6.35B | 98.22 | 1.71% | ― | 0.75% | -20.22% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9996 | 48Neutral | HKD 2.55B | -15.11 | -7.65% | ― | 21.23% | 36.89% |
| HK:2500 | 44Neutral | HKD 432.19M | -0.78 | -28.24% | ― | -38.15% | 25.70% |
| HK:2160 | 43Neutral | HKD 1.63B | -0.86 | -6.69% | ― | ― | ― |
| HK:0853 | 41Neutral | HKD 11.65B | 31.23 | 6.07% | ― | -3.62% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6609 | Shanghai Heartcare Medical Technology Corp. Ltd. Class H | 53.20 | -0.30 | -0.56% | |
| HK:0853 | MicroPort Scientific Corp | 6.08 | -5.92 | -49.33% | |
| HK:9996 | Peijia Medical Ltd. | 3.77 | -2.22 | -37.06% | |
| HK:1302 | LifeTech Scientific Corporation | 1.47 | -0.58 | -28.29% | |
| HK:2160 | MicroPort CardioFlow Medtech Corp. | 1.28 | -4.67 | -78.49% | |
| HK:2500 | Venus Medtech (Hangzhou), Inc. Class H | 0.98 | -1.77 | -64.36% |
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events
Shanghai HeartCare Proposes New Board Term and Adds Non-Executive Director
Shanghai HeartCare Medical Technology Corporation Limited has initiated the process to form its third session of the board of directors, as the current second session is due to expire in November 2026. The proposed new board will comprise nine direct...
Shanghai HeartCare Ties New H Share Incentive Grant to Aggressive Revenue Growth Targets
Shanghai HeartCare Medical Technology Corporation Limited has granted 30,000 H share awards, equal to about 0.10% of its issued H shares, to a single employee under its 2025 H Share Incentive Scheme. The awards carry no issue price and are structured...
Shanghai HeartCare Grants Performance-Tied H Share Awards to Boost Growth
Shanghai HeartCare Medical Technology Corporation Limited, a Hong Kong-listed cardiovascular medical technology provider, is deepening its focus on talent retention and performance-driven culture through equity incentives. The company operates in the...
Shanghai HeartCare Details Voting Results and Governance at 2026 Second EGM
Shanghai HeartCare Medical Technology Corporation Limited reported that its 2026 second extraordinary general meeting was duly convened in Shanghai in accordance with PRC company law and its articles of association, with all directors attending eithe...
Shanghai HeartCare Delivers Robust Interim Growth on Expanding Stroke Device Adoption
Shanghai HeartCare Medical Technology reported strong interim results for the six months ended June 30, 2026, with revenue rising 56.9% to RMB291 million and gross profit climbing 64.3% amid margin expansion. Net profit attributable to shareholders g...
Shanghai HeartCare Sets August Board Meeting to Review Interim Results and Dividend
Shanghai HeartCare Medical Technology Corporation Limited has scheduled a board meeting for August 31, 2026 to review and approve the interim results for the six months ended June 30, 2026 for the company and its subsidiaries. The board will also con...
Shanghai HeartCare Plans A Share Issue and Sci-Tech Board Listing
Shanghai HeartCare Medical Technology Corporation Limited plans to issue up to 7,025,592 A shares and seek a listing on the Sci-Tech Board of the Shanghai Stock Exchange, subject to shareholder approval at an extraordinary general meeting and clearan...
Shanghai HeartCare Seeks Shareholder Approval for Sci-Tech Board A-Share Issuance
Shanghai HeartCare Medical Technology Corporation Limited is a PRC-based medical technology company specializing in cardiovascular solutions, with existing H-share listing in Hong Kong and plans to broaden its investor base. The group aims to leverag...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 08, 2026